APCCC 2019 PRESENTATION SLIDES

Get Free Access to Session Slides

APCCC 2019 VL

Antiresorptive Therapy to Reduce SRE Risk For The Majority of Men with CRPC and Bone Metastases Presentation - Bertrand Tombal

Details
Bertrand Tombal presented the use of antiresorptive therapy to reduce the risk of skeletal-related events (SRE) for the majority of men with castration-resistant prostate cancer (CRPC) and bone metastases. This presentation was part of the debate regarding how aggressive to be with bone-targeted therapy at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 biennial meeting. Dr. Tombal'...

Oligometastatic Prostate Cancer – Definitions and Concepts Presentation - Robert Reiter

Details
Robert Reiter presented the definitions and concepts of oligometastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). With improved imaging, this definition has become important from a terminology and treatment standpoint. Dr. Reiter highlights several potential pathways of oligometastasis from the primary tumor and highlights two important clinical questions r...

The Future of Advanced Prostate Cancer Management: Access to Treatments Presentation - Karim Fizazi

Details
Karim Fizazi presented on global access to treatment of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He includes data on current access to radiotherapy on a worldwide level, the use of generic drugs, including docetaxel, abiraterone, and cabazitaxel expected to start in 2021. Lastly, he highlights the use of surgical castration vs. the use of LHRH ago...

The Future of Advanced Prostate Management Presentation - Mark Rubin

Details
Mark Rubin presents on the future of metastatic prostate cancer in regards to biomarkers at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He discusses both predictive and prognostic biomarkers, currently used biomarker tests, and a summary of some of the many studied biomarkers that are ready and appear promising. In conclusion he shares his beliefs of what we now require which a...

The Future of APC Management in Polymetastatic Disease Presentation - William Oh

Details
In the last 10 years, there has been tremendous progress in the available treatment options for metastatic prostate cancer patients. In this presentation from William Oh at the 2019 Advanced Prostate Cancer Consensus Conference he highlights available treatment options for metastatic prostate cancer patients including serial systemic therapy with combinations of ADT with chemotherapy, abiraterone,...

PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation - Kim Chi

Details
Kim Chi presented an update on the utilization of PARP inhibitors during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types. He...

Treatment of Oligometastatic and Oligoprogressive CRPC Presentation - Eric Small

Details
Eric Small presents on the treatment of oligometastatic and oligoprogressive castration-resistant prostate cancer (CRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Small argues that instead of oligoprogressive CRPC, two other definitions should be used: (i) synchronous oligometastatic CRPC – metastases are synchronous with the emergence of ADT resistance, and (ii) metac...

Oligorecurrent Prostate Cancer Presentation - Piet Ost

Details
Piet Ost discusses the treatment of oligorecurrent prostate cancer after local therapy at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Currently, there is no consensus definition for oligometastatic disease although a consensus working definition is being developed by the EORTC-ESTRO group. Highlighting findings from his own trial, Dr. Ost also frames these two main points durin...

De-Novo Oligometastatic Disease: Consensus and Controversy on Aims, Options, and Rationale Presentation - Michael J. Morris

Details
Michael Morris presented de novo oligometastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019) during the session on PSA Recurrence After Radical Local Therapy and Oligometastatic Prostate Cancer. His presentation highlights trials that support level 1 evidence that AR-directed therapy improves overall survival in M1 disease, trials that have assessed metastasis...

The Future of Advanced Prostate Cancer Imaging Presentation - Stefano Fanti

Details
Stefano Fanti presents his point of view on the future of prostate cancer imaging at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately. Dr. Fanti believes that th...